Outcomes of CD19-directed CAR T-cell therapy in five individuals with multiple sclerosis
Автор: VJNeurology
Загружено: 2025-02-26
Просмотров: 939
Описание:
Johanna Richter, Transplant Physician, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, comments on the preliminary data from her center's experience with a CD19-directed CAR T-cell therapy in five patients with multiple sclerosis (MS). The data indicates mild cytokine release syndrome (CRS) and no immune effector cell-associated neurotoxicity syndrome (ICANS), typical side effects of CAR-T therapies, and expansion-dependent effects on oligoclonal bands. Dr Richter notes that these findings support the safety of CAR T-cell therapy in MS and warrant further study. This interview took place at the EHA-EBMT 7th European CAR T-cell Meeting, held in Strasbourg, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
